FMP
Verrica Pharmaceuticals Inc.
VRCA
NASDAQ
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
0.686 USD
-0.0176 (-2.57%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jayson M. Rieger M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.verrica.comexchange
NASDAQ
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagio...
CIK
0001660334
ISIN
US92511W1080
CUSIP
92511W108
Address
44 West Gay Street
Phone
484 453 3300
Country
US
Employee
100
IPO Date
Jun 15, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
VRCA Financial Summary
CIK
0001660334
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92511W108
ISIN
US92511W1080
Country
US
Price
0.69
Beta
1.46
Volume Avg.
904.52k
Market Cap
62.12M
Shares
-
52-Week
0.611-11.41
DCF
0.38
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.37
P/B
-
Website
https://www.verrica.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VRCA News
It looks like there's no news available.
